Aurobindo Pharma, a prominent pharmaceutical company in India, has appointed T. Vijaya Kumar as President of Research and Development (Specialty Drug Delivery), effective from April 5, 2024. Kumar holds a Master’s degree in Pharmacy (M. Pharm.) with a specialization in Pharmaceutical Technology from Gulbarga University, Gulbarga (India). With nearly 30 years of experience in the pharmaceutical industry, Kumar brings extensive expertise to his new role.
In recognition of his dedication and achievements, Kumar was honored with the prestigious Global Desh Bandhu Gupta Spirit of Lupin Award in 2022 for his commitment to excellence.
Aurobindo Pharma reported a significant year-on-year increase of 90.6 percent in consolidated net profit, amounting to Rs 936.2 crore for the October-December quarter of the current financial year, as announced on February 10.
During the quarter, the company invested a total of Rs 398 crore in research and development (R&D), demonstrating its commitment to innovation and advancement in pharmaceuticals. Additionally, Aurobindo Pharma allocated $103 million for net capital expenditure, including $37 million towards its bulk drugs PLI project, with a total investment of $230 million, and $305 million in its biosimilar project as of December 31, 2023.
On April 5, Aurobindo Pharma’s shares witnessed marginal growth, trading in the green with a slight increase of 0.01 percent at the closing bell, reaching Rs 1,123.70 apiece.
